US8053449B2ExpiredUtilityA1

Method for inhibiting AGE complex formation

76
Assignee: CELL VIABLE CORPPriority: Oct 5, 2005Filed: Oct 2, 2006Granted: Nov 8, 2011
Est. expiryOct 5, 2025(expired)· nominal 20-yr term from priority
Inventors:Jill D. Fabricant
A61K 31/4415A61K 31/426
76
PatentIndex Score
2
Cited by
32
References
7
Claims

Abstract

Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided. Also, a medication releasing medical devices, wherein at least a portion of the medical device releasably includes at least one of these medication(s) are provided.

Claims

exact text as granted — not AI-modified
1. A method of inhibiting the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGE), said method comprising administering to a subject in need of inhibition of advanced glycation end products (AGE), said method comprising administering to a subject in need of inhibition of advanced glycation end product formation at least one medication that inhibits the nonenzymatic formation of AGE complexes wherein said agent is associated with a medical device selected from the group consisting of deposition implants, and medication delivery pumps, and said medication is selected from the group consisting of pyridoxamine, N-phenacylthazolium bromide, alagebrium, and combinations thereof. 
     
     
       2. The method according to  claim 1  wherein said medication further comprises at least one inert pharmaceutical excipient. 
     
     
       3. The method according to  claim 1  wherein said medication comprises a controlled-release profile. 
     
     
       4. The method according to  claim 1  wherein said subject is suffering from diabetes and presents an elevated level of glycosylated hemoglobin in the blood. 
     
     
       5. The method according to  claim 1  wherein said subject is suffering from kidney disease and presents an elevated level of protein in the urine. 
     
     
       6. The method according to  claim 1  wherein said subject is suffering from atherosclerosis and presents an elevated level of cholesterol in the blood. 
     
     
       7. The method according to  claim 1  wherein the medical device is a medication delivery pump.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.